Related Experiment Video

Updated: Apr 27, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K

microRNA and non-canonical TGF-β signalling: implications for prostate cancer therapy

Edward Ottley1, Elspeth Gold1

  • 1Department of Anatomy, University of Otago, Dunedin, New Zealand.

Critical Reviews in Oncology/Hematology
|July 3, 2014
PubMed

Insights

This review explores how microRNAs (miRNAs) affect Transforming Growth Factor-beta (TGF-β) signaling in advanced prostate cancer. Targeting non-canonical TGF-β pathways with miRNAs may offer new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer incidence is rising globally, with advanced stages often resistant to current treatments like androgen deprivation therapy (ADT).
  • Transforming Growth Factor-beta (TGF-β) initially inhibits cancer but becomes ineffective in advanced prostate cancer due to unknown mechanisms of insensitivity.
  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in various cellular processes.

Purpose of the Study:

  • To review the role of microRNAs (miRNAs) in modulating Transforming Growth Factor-beta (TGF-β) signaling pathways in advanced prostate cancer.
  • To investigate the potential of targeting non-canonical TGF-β signaling components (Erk, RhoA, PI3K/Akt, JNK/p38) via miRNAs as a therapeutic strategy.

Main Methods:

  • Literature review focusing on the interplay between miRNAs and TGF-β signaling.
  • Analysis of existing research on miRNA regulation of canonical and non-canonical TGF-β pathways.
  • Exploration of potential therapeutic applications based on miRNA-mediated pathway modulation.

Main Results:

  • MicroRNAs (miRNAs) significantly influence TGF-β signaling, impacting cancer progression.
  • While canonical TGF-β Smad pathway interactions with miRNAs are studied, the role of miRNAs in non-canonical pathways (Erk, RhoA, PI3K/Akt, JNK/p38) is less understood.
  • Dysregulation of these non-canonical pathways by miRNAs may contribute to acquired TGF-β insensitivity in advanced prostate cancer.

Conclusions:

  • MicroRNAs represent a promising avenue for understanding and overcoming therapeutic resistance in advanced prostate cancer.
  • Targeting non-canonical TGF-β signaling pathways through miRNA modulation could offer novel therapeutic strategies for advanced prostate cancer.
  • Further research into miRNA-mediated regulation of non-canonical TGF-β signaling is crucial for developing effective treatments.
Keywords:
Prostate cancerSmad signallingTGF-β superfamilymicroRNA

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.0K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K